Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;26(8):1431-1440.
doi: 10.1007/s10147-021-01911-1. Epub 2021 Apr 9.

The usefulness of microRNA in urine and saliva as a biomarker of gastroenterological cancer

Affiliations
Review

The usefulness of microRNA in urine and saliva as a biomarker of gastroenterological cancer

Isamu Hoshino. Int J Clin Oncol. 2021 Aug.

Abstract

MicroRNA (miR) is a type of short non-coding RNA comprising 21-25 nucleotides. While it has been researched widely, its relationship with cancer was clarified recently and it was found to play a significant role in the development and progression of cancer. Furthermore, miR can remain stable for relatively long periods in the blood by being present in exosomes (extracellular microvesicles) or by forming a complex with the Ago2 protein, which gives rise to cancer-specific miR. It is known that miR can indicate the presence and extent of cancer progression. Several reports have proved that miR in urine and saliva is detected in urinary and oral cancer, respectively, and recent studies have also shown it to be present in cases of gastroenterological cancer, showing evidence of it being a biomarker for cancer. To gather further knowledge on this topic, this review aims to summarize the usefulness of urinary and salivary miR as a biomarker for gastroenterological cancer and discuss its existence, stability mechanism, and direction of future research. The findings will be relevant for physicians and oncologists who routinely treat patients with gastric cancers.

Keywords: Exosome; Gastroenterological cancer; MicroRNA; Saliva; Serum; Urine; miR.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Schochter F, Friedl TWP, deGregorio A et al (2019) Are circulating tumor cells (CTCs) ready for clinical use in breast cancer? An overview of completed and ongoing trials using CTCs for clinical treatment decisions. Cells 8:1412 - PMC - DOI
    1. Lustberg MB, Stover DG, Chalmers JJ (2018) Implementing liquid biopsies in clinical trials: state of affairs, opportunities, and challenges. Cancer J 24:61–64 - PubMed - PMC - DOI
    1. Ignatiadis M, Rack B, Rothé F et al (2016) Liquid biopsy-based clinical research in early breast cancer: the EORTC 90091–10093 treat CTC trial. Eur J Cancer 63:97–104 - PubMed - DOI - PMC
    1. Alunni-Fabbroni M, Rönsch K, Huber T et al (2019) Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J Transl Med 17:328 - PubMed - PMC - DOI
    1. Nicholls JM, Lee VH, Chan SK et al (2019) Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes. Br J Cancer 121:690–698 - PubMed - PMC - DOI

LinkOut - more resources